CN104707127A - Chewable tablet used for relieving and preventing joint diseases and preparation method thereof - Google Patents
Chewable tablet used for relieving and preventing joint diseases and preparation method thereof Download PDFInfo
- Publication number
- CN104707127A CN104707127A CN201510101897.1A CN201510101897A CN104707127A CN 104707127 A CN104707127 A CN 104707127A CN 201510101897 A CN201510101897 A CN 201510101897A CN 104707127 A CN104707127 A CN 104707127A
- Authority
- CN
- China
- Prior art keywords
- glucosamine
- hyaluronic acid
- micromolecule hyaluronic
- chondroitin sulfate
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a chewable tablet used for relieving and preventing joint diseases and a preparation method thereof. The invention relates to a composition, particularly to a chewable tablet prepared from glucosamine, chondroitin sulfate, milk minerals, casein phosphopeptides and micromolecule hyaluronic acid, and application of the chewable tablet in preventing and curing joint diseases.
Description
Technical field
The invention belongs to the field of bio-pharmaceuticals, particularly relate to a kind of for alleviating and preventing arthritic glucosamine chewable tablet and preparation method thereof.
Background technology
Osteoarthritis is a kind of systemic autoimmune diseases being feature with chronic erosive arthritis, and its lesion characteristic is synovitis, and the articular cartilage caused thus and bone destruction, finally causes joint deformity.Nearest investigational data display, global rheumatisant about has 400,000,000 people, is a disease group the hugest in medical domain.
In recent years, along with people's going deep into osteoporosis study of incident mechanism, there is increase bone density, prevent chondrocyte injury, promote the repair and reconstruction of cartilage matrix, improve the material of joint motion, anti-inflammatory and analgesic effect, because of the mechanism of action that it is unique, safe and reliable, be more and more subject to people's favor.
Summary of the invention
The object of this invention is to provide a kind of alleviation and prevent arthritic glucosamine composition and preparation method thereof.
The present composition is made up of glucosamine, chondroitin sulfate, newborn mineral salt, phosphopeptide caseinate, micromolecule hyaluronic acid.Significant synergism is had between various component.The technology screening routinely of preferred each component, granulation, make chewable tablet in proportion.
In formula of the present invention, the Main Function of each raw material is described below:
1, glucosamine: it is the material of synthesis in human body, being the important nutrient forming chondrocyte, is the natural tissues composition of healthy articular cartilage.With advancing age, the shortage of the glucosamine in human body is more and more serious, and articular cartilage is constantly degenerated and worn and torn.A large amount of medical research shows: glucosamine can help repair and safeguard cartilage, and can stimulate the growth of chondrocyte, thus can delay or reverse the pathological process of osteoarthritis and the progress of disease, improves joint motion, alleviating pain.
2, micromolecule hyaluronic acid and salt (hyaluronan thereof, HA): hyaluronate sodium is the polymer substance being extensively present in people and the various tissue of animal, it is a kind of high viscosity material, HA has extraordinary biocompatibility, be the main component forming articular cartilage and synovial fluid, vital effect is played to the performance of joint physiological function.
HA application clinically depends on the size of its molecular weight, and average relative molecular mass is several thousand-400 ten thousand.Micromolecule hyaluronic acid comes into one's own day by day in recent years, and it has its characteristics and advantages relative to HA that is high, middle-molecular-weihydroxyethyl: be mainly reflected in:
1) micromolecule hyaluronic acid can infiltrate corium, has mild dilation blood capillary, increases blood circulation, improves intermediate supersession, promotes skin-nourishing Absorption, have stronger wrinkle-chasing function, can increase skin elasticity, delay skin aging.
2) micromolecule hyaluronic acid can also promote the propagation of epidermis cell and differentiation, scavenging activated oxygen, can prevent and repair skin injury.
3) micromolecule HA has stronger permeability and absorbability, hyaluronic supplementary more convenient to endogenous, is of high nutritive value.
The hyaluronic acid that the present invention uses uses micromolecule hyaluronic acid, and its molecular weight ranges is 5000 ~ 500000.
3, chondroitin sulfate: be the covalently bound class glycosaminoglycans forming Dan Baiduotang proteoglycan PG on protein.Chondroitin sulfate is distributed widely in extracellular matrix and the cell surface of animal tissue, sugar chain is made up of the glucuronic acid replaced and N-acetylgalactosamine (also known as N-acetylamino galactosamine) disaccharide unit, is connected on the serine residue of core protein like sugared link zone by one.Medically main application approach be as treatment joint disease medicine, with glucosamine with the use of, there is pain relieving, lubrication and support joint, promotion regenerating bone or cartilage effect, can from improving joint prob at all.
4, newborn mineral salt: newborn mineral salt is a kind of new resource food, refers to milk surum to be raw material, the supplementary being beneficial to absorption of human body made through removing the composition milk basic protein such as protein, lactose.Breast mineral salt is separated from milk, and natural, safety, natural milk fragrance is more easily esthetically acceptable to the consumers.Stimulate little to the intestines and stomach, effectively can be absorbed and utilization by human body.Close with the composition of skeleton tooth, rational calcium-phosphorus ratio makes effect of supplemented calcium better.Effect of supplemented calcium can not take a turn for the worse, and still keep, and the bone density that inorganic calcium stopping has increased after supplementing can fade away even if the bone density of increase supplements newborn mineral salt in stopping after 3 years.
5, phosphopeptide caseinate (Casein Phosphopeptides is called for short CPP): phosphopeptide caseinate is through proteolysis separating-purifying in milk casein, and then the peptide material of spraying dry.It effectively can improve the intake of the divalent minerals such as human calcium, ferrum, zinc and absorption and utilization rate, can prevent and improve osteoporosis, promote the rehabilitation of fracture patient.
About aminoglucose saccharide health product, forefathers have also been made large quantifier elimination, combine as patent CN200410025589 reports a kind of glucosamine and salt thereof and hyaluronic acid and salt thereof, and result of use is better than and is used alone glucosamine or hyaluronic acid; CN101690727 also provides hyaluronic acid and glucosamine oral formulations carrys out treatment of arthritis; Patent CN102224896 provides a kind of preparation being become to be grouped into by hyaluronic acid, glucosamine, collagen protein, Radix Puerariae extract, chondroitin sulfate, vitamin, calcium etc., for increasing body immunity and increase bone density; CN201410353807 discloses one and comprises the compositionss such as glucosamine, newborn mineral salt, hydrolytic collagen, Rhizoma Curcumae Longae extract, phosphopeptide caseinate, protects skeleton, strong skeleton.
But the medicine containing treatment of arthritis such as glucosamine sold in the market is nearly all the form of tablet or hard capsule, there is mouthfeel difference, difficult disintegrate, onset slowly in product, bioavailability is low, is difficult to problems such as being absorbed by the body.Above-mentioned composition is prepared into the form of chewable tablet by the present invention, the problem that when conventional tablet medicine reaches the intestines and stomach, just slowly disintegrate emission and absorption is slow is solved by chewing, improve the drug effect of active drug, decrease the discomfort that gastrointestinal burden is caused, have that mouthfeel is good, bioavailability is high, can product efficacy be given full play to.
In sum, glucosamine hydrochloride, hyaluronate sodium, newborn mineral salt, chondroitin sulfate, phosphopeptide caseinate five kinds of compositions, all can play good curative effect in increase bone density.Pertinent literature is reported, if with the use of playing better synergism, more easily promote the absorption of calcium, can increase bone density better, the present invention is prepared into chewable tablet by above-mentioned five kinds of compositions, for alleviating and prevention joint disease.
In view of this, we test through repeatedly deep investigation and comparison, determine and above-mentioned micromolecule hyaluronic acid (molecular weight ranges is 5000 ~ 500000), glucosamine, newborn mineral salt, phosphopeptide caseinate, chondroitin sulfate are combined, combine according to a certain percentage, complete to have and alleviate and prevent the arthritic present composition, the proportioning (by weight) of described content is:
Glucosamine 1-90%
Chondroitin sulfate 1-90%
Breast mineral salt 1-90%
Phosphopeptide caseinate 1-90%
Micromolecule hyaluronic acid sodium 1-50%
Other adjuvants 0.2-50%
The optimum ratio (by weight) of each component of the present composition is:
Glucosamine 10-45%
Chondroitin sulfate 10-25%
Breast mineral salt 10-50%
Phosphopeptide caseinate 5-20%
Micromolecule hyaluronic acid sodium 1-10%
Other adjuvants 0.2-30%
The further optimum ratio of each component of the present composition (by weight) is:
Glucosamine 20.0%
Chondroitin sulfate 12.5%
Breast mineral salt 30.0%
Phosphopeptide caseinate 15.0%
Micromolecule hyaluronic acid sodium 1.6%
Other adjuvants 20.9%
The further optimum ratio of each component of the present composition (by weight) is:
Glucosamine 20.0%
Chondroitin sulfate 12.5%
Breast mineral salt 30.0%
Phosphopeptide caseinate 15.0%
Micromolecule hyaluronic acid sodium 1.6%
Xylitol 17.5%
Sucralose 1.4%
Essence 1.0%
Magnesium stearate 1.0%
The glucosamine of this compositions comprises glucosamine or its hydrochlorate, sulfate monomer or sulphuric acid potassium salt, sodium sulfate salt etc., also can be the aminoglucose sugar derivativess such as 2-Acetamido-2-deoxy-D-glucose dimethoxym ethane, 2-Acetamido-2-deoxy-D-glucose.
This compositions micromolecule hyaluronic acid comprises micromolecule hyaluronic acid or its slaine, is good especially with sodium salt.
The present composition is according to after aforementioned proportion mixing, according to certain preparation process, add the conventional adjuvant such as excipient, flavoring agent, disintegrating agent, antiseptic, lubricant, wetting agent, adhesive, solvent, thickening agent, solubilizing agent, sieve, granulate, tabletting makes chewable tablet, make medicine or health food further.
Form is described in further detail content of the present invention more by the following examples, but should not be interpreted as in the above-mentioned subject area of the present invention at this point and be only limitted to following examples.Do not departing under the above-mentioned technology prerequisite of the present invention, the corresponding replacement made according to ordinary skill knowledge and customary means or the amendment of change, include within the scope of the invention
.
embodiment one
Following examples illustrate and contrast actual effect of the present invention
Above-mentioned formula is made chewable tablet, the every sheet of 1.6g, each 2, one day twice.
Apply above-mentioned prescription to implement to prevent and treat osteoarthritis effect.
Select osteoarthritis patient 150 people, be divided into preparation A group, preparation B group, formulation C group, preparation D group, preparation E group at random, often organize 30 examples, between each group of patient, the physical data such as sex, age, state of an illness does not have significant difference (P>0.05), has comparability.Often group takes corresponding preparations, each 2, every day 2 times, 6 weeks courses for the treatment of.Utilize Osteoarthritis Index (WOMAC) to evaluate, comprise pain, stiff and function of joint, each item rating score value is that 0-4 divides.
Result is as shown in the table, each index decline percentage ratio after numeral treatment in table
| Group | Pain | Stiff | Function of joint |
| A group | 15 | 18 | 20 |
| B group | 36 | 38 | 34 |
| C group | 23 | 25 | 18 |
| D group | 55 | 53 | 43 |
| E race | 52 | 51 | 38 |
Conclusion: find out from upper table, glucosamine and chondroitin sulfate preparation all have good effect to orthopaedic disease, but the effectiveness comparison of A group and B group, B group adds the clinical symptoms that hyaluronate sodium significantly improves patient, C group does not add hyaluronate sodium, effect and A group compare, increase, but not as good as adding hyaluronic acid successful, D group and E group are five kinds of compositions, effect than above three groups more obvious, absolutely proving that five kinds of compositions have obvious synergism, having obvious effect to improving osteopathia.
embodiment two
Glucosamine tablet formulation (preparing 1250)
Glucosamine 400g
Chondroitin sulfate 250g
Breast mineral salt 600g
Phosphopeptide caseinate 300g
Micromolecule hyaluronic acid sodium 32g
PVP K30 38g
Magnesium stearate 10.0g
Lactose 370g
Preparation technology: 1) take glucosamine, chondroitin sulfate, newborn mineral salt, phosphopeptide caseinate, micromolecule hyaluronic acid sodium, lactose, mix homogeneously; 2) pulverize and sieve, again mix homogeneously; 3) make suitable soft material with the PVP K30 alcoholic solution of 10%, sieve; 4) less than 60 DEG C dryings; 5) magnesium stearate is added, mix homogeneously, granulate; 6) tabletting, control strip weight.
embodiment three
Glucosamine granule prescription (preparing 1250)
Glucosamine 400g
Chondroitin sulfate 250g
Breast mineral salt 650g
Phosphopeptide caseinate 250g
Micromolecule hyaluronic acid 32g
Xylitol 380g
Sucralose 10g
Magnesium stearate 8g
Spice 20g
Preparation technology: 1) take glucosamine, chondroitin sulfate, newborn mineral salt, phosphopeptide caseinate, micromolecule hyaluronic acid sodium, xylitol, mix homogeneously; 2) pulverize and sieve, again mix homogeneously; 3) sucralose is dissolved in 50% ethanol, adds the above-mentioned material pulverized and sieved, make suitable soft material, granulation of sieving; 4) 50-60 DEG C of drying, sieve granulate; 5) magnesium stearate, spice is added, mix homogeneously, tabletting, packaging.
Claims (9)
1. a compositions, is characterized in that said composition is made up of glucosamine, chondroitin sulfate, newborn mineral salt calcium, phosphopeptide caseinate, micromolecule hyaluronic acid.
2. compositions according to claim 1, it is characterized in that glucosamine comprises glucosamine or its hydrochlorate, sulfate monomer or sulphuric acid potassium salt, sodium sulfate salt etc., also can be the aminoglucose sugar derivativess such as 2-Acetamido-2-deoxy-D-glucose dimethoxym ethane, 2-Acetamido-2-deoxy-D-glucose.
3. compositions according to claim 1, is characterized in that micromolecule hyaluronic acid comprises micromolecule hyaluronic acid or its slaine, and be good with sodium salt especially, the molecular weight ranges of micromolecule hyaluronic acid is 5000 ~ 500000.
4., according to compositions described in claim 1, it is characterized in that the proportioning (by weight) of each component of said composition is:
Glucosamine 1-90%
Chondroitin sulfate 1-90%
Breast mineral salt 1-90%
Phosphopeptide caseinate 1-90%
Micromolecule hyaluronic acid sodium 1-50%
Other adjuvants 0.2-50%.
5., according to compositions described in claim 1, it is characterized in that the proportioning (by weight) of each component of said composition is:
Glucosamine 10-45%
Chondroitin sulfate 10-25%
Breast mineral salt 10-50%
Phosphopeptide caseinate 5-20%
Micromolecule hyaluronic acid sodium 1-10%
Other adjuvants 0.2-30%.
6., according to compositions described in claim 1, it is characterized in that the proportioning (by weight) of each component of said composition is:
Glucosamine 20.0%
Chondroitin sulfate 12.5%
Breast mineral salt 30.0%
Phosphopeptide caseinate 15.0%
Micromolecule hyaluronic acid sodium 1.6%
Other adjuvants 20.9%.
7., according to compositions described in claim 1, it is characterized in that the proportioning (by weight) of each component of said composition is:
Glucosamine 20.0%
Chondroitin sulfate 12.5%
Breast mineral salt 30.0%
Phosphopeptide caseinate 15.0%
Micromolecule hyaluronic acid sodium 1.6%
Xylitol 17.5%
Sucralose 1.4%
Essence 1.0%
Magnesium stearate 1.0%.
8. the present composition is according to after aforementioned proportion mixing, according to certain preparation process, add the conventional adjuvant such as excipient, flavoring agent, disintegrating agent, antiseptic, lubricant, wetting agent, adhesive, solvent, thickening agent, solubilizing agent, make chewable tablet, make medicine or health food further.
9. the compositions be made up of glucosamine, chondroitin sulfate, newborn mineral salt, phosphopeptide caseinate, micromolecule hyaluronic acid is preparing the application prevented and treated in osteoarthritis preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510101897.1A CN104707127A (en) | 2015-03-09 | 2015-03-09 | Chewable tablet used for relieving and preventing joint diseases and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510101897.1A CN104707127A (en) | 2015-03-09 | 2015-03-09 | Chewable tablet used for relieving and preventing joint diseases and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104707127A true CN104707127A (en) | 2015-06-17 |
Family
ID=53407171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510101897.1A Pending CN104707127A (en) | 2015-03-09 | 2015-03-09 | Chewable tablet used for relieving and preventing joint diseases and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104707127A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113230381A (en) * | 2021-06-01 | 2021-08-10 | 杭州丽昌农业科技有限公司 | Formula for increasing bone mineral density |
| CN114533654A (en) * | 2021-12-29 | 2022-05-27 | 南京乐韬生物科技有限公司 | Low-molecular chondroitin sulfate composite hydrogel and preparation method and application thereof |
| CN114732131A (en) * | 2022-04-19 | 2022-07-12 | 山东焦点福瑞达生物股份有限公司 | Composite hyaluronic acid composition for preventing and relieving joint diseases |
| IT202100030935A1 (en) | 2021-12-09 | 2023-06-09 | Fidia Farm Spa | TABLETS INCLUDING CHONDROITIN SULFATE, GLUCOSAMINE HYDROCHLORIDE AND VITAMIN C FOR THE TREATMENT OF CARTILAGE, TENDON AND BONE DAMAGE |
| US20240189228A1 (en) * | 2017-10-31 | 2024-06-13 | Sofar Swiss Sa | Suckable and/or melt-in-mouth tablet based on hyaluronic acid and chondroitin sulphate and salts thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101181294A (en) * | 2007-06-22 | 2008-05-21 | 北京星昊医药股份有限公司 | Pharmaceutical composition for curing osteoarthritis |
| CN101543245A (en) * | 2008-03-24 | 2009-09-30 | 内蒙古伊利实业集团股份有限公司 | Neutral liquid high calcium milk and preparation method thereof |
| CN103735572A (en) * | 2012-10-17 | 2014-04-23 | 山东明仁福瑞达制药股份有限公司 | Composition having bone mineral density increasing function, anti-inflammatory function and analgesia function, and preparation method of the composition |
| CN103751767A (en) * | 2013-12-15 | 2014-04-30 | 青岛东海药业有限公司 | Medicament composition and application thereof |
| CN104162150A (en) * | 2014-07-23 | 2014-11-26 | 北京中泰天和科技有限公司 | Composition having bone mineral density increasing function and preparation method thereof |
-
2015
- 2015-03-09 CN CN201510101897.1A patent/CN104707127A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101181294A (en) * | 2007-06-22 | 2008-05-21 | 北京星昊医药股份有限公司 | Pharmaceutical composition for curing osteoarthritis |
| CN101543245A (en) * | 2008-03-24 | 2009-09-30 | 内蒙古伊利实业集团股份有限公司 | Neutral liquid high calcium milk and preparation method thereof |
| CN103735572A (en) * | 2012-10-17 | 2014-04-23 | 山东明仁福瑞达制药股份有限公司 | Composition having bone mineral density increasing function, anti-inflammatory function and analgesia function, and preparation method of the composition |
| CN103751767A (en) * | 2013-12-15 | 2014-04-30 | 青岛东海药业有限公司 | Medicament composition and application thereof |
| CN104162150A (en) * | 2014-07-23 | 2014-11-26 | 北京中泰天和科技有限公司 | Composition having bone mineral density increasing function and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 邵胜荣 等: "乳矿物盐软胶囊的工艺研究", 《食品开发》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240189228A1 (en) * | 2017-10-31 | 2024-06-13 | Sofar Swiss Sa | Suckable and/or melt-in-mouth tablet based on hyaluronic acid and chondroitin sulphate and salts thereof |
| CN113230381A (en) * | 2021-06-01 | 2021-08-10 | 杭州丽昌农业科技有限公司 | Formula for increasing bone mineral density |
| IT202100030935A1 (en) | 2021-12-09 | 2023-06-09 | Fidia Farm Spa | TABLETS INCLUDING CHONDROITIN SULFATE, GLUCOSAMINE HYDROCHLORIDE AND VITAMIN C FOR THE TREATMENT OF CARTILAGE, TENDON AND BONE DAMAGE |
| CN114533654A (en) * | 2021-12-29 | 2022-05-27 | 南京乐韬生物科技有限公司 | Low-molecular chondroitin sulfate composite hydrogel and preparation method and application thereof |
| CN114533654B (en) * | 2021-12-29 | 2023-11-21 | 南京乐韬生物科技有限公司 | Low-molecular chondroitin sulfate composite hydrogel and preparation method and application thereof |
| CN114732131A (en) * | 2022-04-19 | 2022-07-12 | 山东焦点福瑞达生物股份有限公司 | Composite hyaluronic acid composition for preventing and relieving joint diseases |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104645332A (en) | Pharmaceutical composition for relieving and preventing arthritis | |
| KR101325374B1 (en) | Oral or enteral composition useful for recovery of physical functions | |
| CN104707127A (en) | Chewable tablet used for relieving and preventing joint diseases and preparation method thereof | |
| CN104188999A (en) | Composition capable of increasing bone density and improving functions of skeletons and joints and preparation method thereof | |
| CN101181294A (en) | Pharmaceutical composition for curing osteoarthritis | |
| CN102949710B (en) | Pharmaceutical composition or healthcare product for increasing bone mineral density and preparation method of pharmaceutical composition or healthcare product | |
| CN103735572A (en) | Composition having bone mineral density increasing function, anti-inflammatory function and analgesia function, and preparation method of the composition | |
| CN110946874A (en) | Hyaluronic acid composition for relieving osteoarthritis | |
| WO2013136871A1 (en) | Oversulfated chondroitin composition | |
| CN111467481A (en) | Composition for improving and/or preventing osteoarthritis and application thereof | |
| CN106072651A (en) | A kind of have compositions increasing bone density, anti-inflammatory and analgesic effect and preparation method thereof | |
| CN108112997B (en) | A health food composition | |
| CN104721805A (en) | Granules for alleviating and preventing joint diseases and preparation method thereof | |
| TWI520740B (en) | Treatment of bone marrow edema (oedema) with polysulfated polysaccharides | |
| CN106262809A (en) | A kind of bone density that strengthens alleviates the compositions of person in middle and old age's arthralgia | |
| CN101455396A (en) | Nutrient health-care food capable of promoting bone and bone arthrosis health | |
| CN102441023B (en) | Injection composition for treating orthopedic diseases | |
| CN116726141A (en) | Composition for preventing and relieving osteoarthropathy and application thereof | |
| CN105982911A (en) | Preparation method of high-viscoelasticity injection composed of glucosamine and sodium hyaluronate | |
| CN108815505A (en) | Improve the composition that middle-aged and the old's bone density and osteoarticular function avoid waist-leg from knotting | |
| ES2449071T3 (en) | Composition for the treatment of osteoarthritis | |
| CN103877140A (en) | Application of saussurea involucrate culture in preparation of product for promoting bone health | |
| CN105831738A (en) | Polypeptide glucosamine chondroitin nutritional health food | |
| CN105267949A (en) | Medicine prescription for degenerative arthritis and osteoporosis and tablet preparation method thereof | |
| CN105030900A (en) | Externally used paste for treating rheumatic and rheumatoid arthritis and its preparation method and use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150617 |
|
| RJ01 | Rejection of invention patent application after publication |